First Milestone Payment. Within thirty (30) days of the issuance of the first Regulatory Approval for the use of a Licensed Product in a Major Market, other than for PSMA and/or PSMP, NWBio shall pay Cytogen the sum of * .
First Milestone Payment. Licensee shall pay Licensor [***] dollars ($[***]) which shall include (i) [***] dollars ($[***]) in cash and (ii) [***] dollars ($[***]) in cash or [***] dollars ($[***]) in the form shares of a new series of preferred stock of the Licensee (such shares of such new series of [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED preferred stock to be specific for this milestone payment and equivalent to the Common Stock in all respects except that such series of preferred stock will rank senior to the Common Stock and that the per share price of each share of such new series of preferred stock shall be equal to that paid by the Licensee's then most recent equity investor), such form of payment to be determined by the Licensee and the Licensor through discussions and upon reaching a reasonable agreement, upon demonstration of human clinical efficacy of a Product by Licensee or its Sub - licensee (i.e., transition from Phase II to Phase III trials, which shall be indicated by enrollment of the first five patients in a pivotal Phase III trial) in at least one indication of the following indications: MAC in AIDS patients, M. tuberculosis, H. Pylori in Peptic ulcer patients, Chlamydia pneumoniae in Multiple Sclerosis or Atherosclerosis, Chlamydia trachomatis in Sexually Transmitted Disease or Community acquired pneumonia patients or Staphylococcus aureus infection.
First Milestone Payment. (i) Subject to adjustment pursuant to Section 2.8(b)(iii) and further subject to the provisions of Section 2.8(e) and Section 2.8(f) below, upon First Patient Dosage (the “First Milestone”), Acquiror agrees to issue to the Target Stockholders the First Milestone Stock Payment.
First Milestone Payment. (a) Notwithstanding anything to the contrary in the Purchase Agreement, Seller desires to, and hereby does, waive any and all rights as to the First Milestone Payment. Purchaser and Agent hereby acknowledge and accept such waiver.
First Milestone Payment. Upon the execution of this Agreement by all Parties, the Collaboration Receivable Amount shall be automatically reduced by $10,000,000 (the “First Milestone Payment”).
First Milestone Payment. Parent shall make a one-time Milestone Payment to the Company Securityholders equal to $20,000,000 (the “Relaunch Milestone Payment”), to be paid in Parent Shares in accordance with Section 2.16(c), on or prior to the 20th Business Day following the date upon which Parent or any Subsidiary of Parent has received approval from the required Governmental Authorities to recommence sales on an unrestricted basis (in the same manner as approved prior to its suspension) in the European Union of Surgical Systems that use the Synergy System (the “Relaunch” and such approval from the required Governmental Authorities, the “Relaunch Approval”); provided, that the Relaunch Milestone Payment shall be reduced by $200,000 for each clinical case that is required by the applicable Governmental Authorities prior to receiving the Relaunch Approval (each, a “Clinical Case”) in excess of ten Clinical Cases (i.e., if eleven (11) Clinical Cases are required, then the Relaunch Milestone Payment shall be reduced to $19,800,000); provided, further, that not more than 20 Clinical Cases are required prior to receiving Relaunch Approval.
First Milestone Payment. Subject to Article VIII, on the First Milestone Completion Date, Purchaser shall deliver or caused to be delivered to Seller, the First Milestone Amount (if any);
First Milestone Payment. On the Original Agreement Effective Date, HMR shall pay to P&G *****.
First Milestone Payment. Upon MHLW Marketing Authorization of a ThermoDox Product for HCC in the Territory, Yakult shall pay Celsion Eighteen Million United States Dollars ($18,000,000 (US); the “First Milestone Payment”). [ * ].
First Milestone Payment. As set forth in Section 3.2, the Project Company shall remit the first Milestone Payment to the SunEdison EPC Party within ten (10) Business Days following the delivery of the Confirmation Notice.
